Abstract
United Therapeutics will report results on August 05, 2026 Pre-Market; our preview compiles the latest quarterly actuals and the company’s forward-looking metrics alongside recent institutional commentary to frame expectations and key swing factors for the print.
Market Forecast
Consensus for the current quarter points to revenue of 805.65 million US dollars, an EBIT of 388.57 million US dollars, and EPS of 6.83, implying year-over-year changes of 0.17%, 5.39%, and -1.56%, respectively. The revenue outlook implies a broadly stable top line, while margins remain supported by the company’s high-value pulmonary arterial hypertension portfolio; adjusted EPS is expected to be modestly lower on mix and operating investment. Last quarter’s gross profit margin was 82.93% and net profit margin was 35.18%; absent explicit guidance for the current quarter, we assume margins remain broadly resilient around these levels.
The main business continues to be propelled by the Tyvaso franchise across DPI and nebulized forms and legacy prostacyclin therapies. The most promising growth segment is Tyvaso DPI, with last quarter revenue of 330.30 million US dollars and a robust year-over-year expansion trend signaled by portfolio mix, positioning it to anchor incremental growth this quarter.
Last Quarter Review
United Therapeutics posted revenue of 781.50 million US dollars, a gross profit margin of 82.93%, GAAP net profit attributable to the parent company of 275.00 million US dollars, a net profit margin of 35.18%, and adjusted EPS of 5.82, reflecting a year-over-year EPS change of -12.22% and revenue change of -1.62%.
A key highlight was continued mix shift toward inhaled prostacyclin formulations, with Tyvaso DPI emerging as the top single product contributor. By business line, Tyvaso DPI delivered 330.30 million US dollars, Nebulized Tyvaso 127.20 million US dollars, Remodulin 126.60 million US dollars, and Unituxin 53.60 million US dollars, underscoring inhaled therapies as the primary revenue engine.
Current Quarter Outlook
Main pulmonary hypertension portfolio
The current quarter hinges on sustained utilization of the Tyvaso family across both interstitial lung disease and pulmonary arterial hypertension patients. Demand indicators embedded in the revenue estimate of 805.65 million US dollars suggest a flattish sequential trajectory following a softer prior quarter, pointing to steady prescription volumes and stable patient retention. Given the structural advantages of inhaled prostacyclins and persistent unmet need in chronic pulmonary indications, we expect revenue durability and mix resilience to help maintain gross margins near the prior quarter’s 82.93% level. Any deviation in payer dynamics or inventory movements could nudge recognized revenues, but the franchise’s breadth still provides a buffer to short-term variability.
Tyvaso DPI as the leading growth vector
Tyvaso DPI remains the largest growth contributor within the portfolio, supported by favorable patient adherence characteristics and broadened prescriber familiarity. With last quarter sales at 330.30 million US dollars, even moderate sequential growth could disproportionately influence consolidated revenue and EBIT this quarter, given the product’s scale and margin profile. We expect clinical uptake in interstitial lung disease settings to remain a key catalyst, with incremental share gains off nebulized conversions sustaining momentum. Risks cluster around competitive dynamics and any supply constraints, but the balance of evidence points to continued franchise expansion.
Key stock price swing factors this quarter
Investor attention focuses on operating margin trajectory relative to the prior quarter’s 35.18% net margin baseline and whether operating expense reinvestment tempers near-term EPS. The consensus EPS of 6.83 implies a slight year-over-year decline despite a broadly stable revenue base, suggesting higher spend behind commercialization and pipeline progress. Upside could emerge if revenue mix skews more heavily to high-margin DPI sales or if operating efficiencies outperform; downside may stem from higher-than-modeled spending or any adverse shifts in specialty pharmacy channel inventories. Management commentary on patient adds, conversion rates, and payer developments will be critical for recalibrating out-quarter expectations.
Analyst Opinions
Across recent institutional commentary, the majority view is bullish, emphasizing the durability of the Tyvaso franchise and margin resilience into the current quarter. Analysts highlight that the projected revenue of roughly 805.65 million US dollars with an EBIT of 388.57 million US dollars leaves room for upside if Tyvaso DPI adoption continues to outpace expectations and if operating expenses remain controlled relative to plan. Well-followed research desks point to improving mix toward higher-value inhaled therapies and a robust cash generation profile as key supports for earnings quality. The prevailing view expects stable to improving gross margins anchored by product mix, with a balanced stance on EPS given reinvestment needs; investors will be looking for management to quantify patient growth trajectories and comment on any competitive read-throughs. On balance, bullish opinions outweigh neutral and cautious stances, with the consensus framing this quarter as a validation point for sustained DPI-led growth.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments